NovoMab BioPharmaceuticals Inc CTLA-4 Antibody Patent US12606624B2
Summary
The USPTO granted Patent US12606624B2 to NovoMab BioPharmaceuticals Inc covering an antibody that specifically binds to human CTLA-4. The patent discloses three complementarity-determining regions (CDR1-3) and applications in medicaments and kits for potential tumor growth inhibition. The patent application (18456503) was filed on August 27, 2023.
What changed
The USPTO issued Patent US12606624B2 to NovoMab BioPharmaceuticals Inc for an anti-CTLA-4 antibody. The patent specifies three complementarity-determining regions with amino acid sequences SEQ ID NO:1, 2, and 3, and covers medicaments and kits comprising the antibody.
For biopharmaceutical companies engaged in antibody development, this patent establishes proprietary protections around CTLA-4 targeting technology. Organizations developing immunotherapies should review their pipeline to assess potential overlap with the disclosed CDR sequences and applications including tumor growth inhibition.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Antibody that specifically binds to human CTLA4 and medicaments and kits comprising the same
Grant US12606624B2 Kind: B2 Apr 21, 2026
Assignee
NovoMab BioPharmaceuticals Inc
Inventors
Weiliang Zhuang, Lili Pei
Abstract
The present invention discloses an antibody that specifically binds to human CTLA4, comprising three complementarily-determining regions; the three complementarity-determining regions are respectively: CDR1 with an amino acid sequence as shown in SEQ ID NO: 1, CDR2 with an amino acid sequence as shown in SEQ ID NO: 2, and CDR3 with an amino acid sequence as shown in SEQ ID NO: 3. Also disclosed are medicaments and kits comprising the antibodies described above. The antibodies of the present invention exhibit, but are not limited to, the following properties: (1) high affinity and specificity with human CTLA4; (2) able to block the interaction of CTLA4 with CD86 or CD80; (3) able to specifically bind to CTLA4 overexpressing cells; (4) enhancing activation of PBMC and/or T cells; (5) inhibiting tumor growth.
CPC Classifications
C07K 16/2818 C07K 2317/52 C07K 2317/565 C07K 2317/622 C07K 2317/22 C07K 2317/24 C07K 2317/569 C07K 2317/76 C07K 2317/92 C07K 2317/732 C07K 2317/94 A61P 35/00 A61P 31/00 A61P 33/00 A61K 2039/505
Filing Date
2023-08-27
Application No.
18456503
Claims
12
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.